Insider Selling: BeOne Medicines (NASDAQ:ONC) CEO Sells $980,676.15 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 3,693 shares of the stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $265.55, for a total transaction of $980,676.15. Following the completion of the transaction, the chief executive officer directly owned 2,043 shares in the company, valued at approximately $542,518.65. This represents a 64.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Oyler also recently made the following trade(s):

• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total value of $501,360.76.
• On Monday, June 8th, John Oyler sold 4,940 shares of BeOne Medicines stock. The shares were sold at an average price of $270.56, for a total value of $1,336,566.40.

BeOne Medicines Price Performance

Shares of NASDAQ ONC opened at $270.15 on Friday. The firm has a market cap of $29.64 billion, a P/E ratio of 60.44 and a beta of 0.49. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. BeOne Medicines Ltd. – Sponsored ADR has a 1-year low of $239.25 and a 1-year high of $385.22. The business’s 50 day moving average is $295.32 and its 200-day moving average is $312.15.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The business had revenue of $1.51 billion during the quarter. Equities research analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 6.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on ONC shares. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a research report on Monday, April 20th. Guggenheim raised their price target on shares of BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Morgan Stanley reiterated an “overweight” rating and issued a $395.00 price objective on shares of BeOne Medicines in a research note on Thursday, May 7th. Royal Bank Of Canada boosted their price objective on shares of BeOne Medicines from $425.00 to $436.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Finally, Wells Fargo & Company began coverage on shares of BeOne Medicines in a research report on Monday, May 4th. They set an “overweight” rating and a $400.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, BeOne Medicines currently has a consensus rating of “Moderate Buy” and a consensus price target of $390.00.

Institutional Trading of BeOne Medicines

Several large investors have recently modified their holdings of ONC. EFG International AG acquired a new position in BeOne Medicines in the fourth quarter valued at about $25,000. Leonteq Securities AG acquired a new stake in BeOne Medicines during the fourth quarter worth about $35,000. Daiwa Securities Group Inc. acquired a new stake in BeOne Medicines during the second quarter worth about $35,000. CWM LLC increased its holdings in BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after buying an additional 39 shares during the period. Finally, Group One Trading LLC bought a new position in BeOne Medicines in the 4th quarter valued at about $61,000. 48.55% of the stock is owned by institutional investors and hedge funds.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.